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BACKGROUND
RESULTS
CONCLUSIONS
► ARQ 087 is a multi-kinase inhibitor designed to
preferentially inhibit the fibroblast growth factor receptor
(FGFR) family
► ARQ 087, an orally bioavailable, ATP-competitive
compound, is a dual kinase inhibitor that binds to the
inactive form of FGFR1 and FGFR2 and potently inhibits the
active forms of FGFR1 and FGFR2
► Intrahepatic cholangiocarcinoma (iCCA) is associated with
very poor prognosis, high mortality rate and limited
treatment options
► Molecular characterization of iCCA by next generation
sequencing (NGS) or fluorescence in situ hybridization
(FISH) has enabled identification of actionable genetic
alterations1
► FGFR2 fusion, a novel genetic translocation, has been
recently implicated in the development and progression of
iCCA, and recognized as a potential therapeutic target
 Patients with advanced or inoperable iCCA have a poor prognosis and limited treatment options. A number of selective and multi-kinase FGFR inhibitors are
currently under development for FGFR-driven tumors such as iCCA. ARQ 087 has a potent biochemical activity against the FGFR2 kinase and has demonstrated in
vitro efficacy in models with FGFR2 fusion4
 In the 12 evaluable patients with iCCA with FGFR2 fusion:
o The objective response rate was 25% (3 PR) and disease control rate was 75% (PR+SD)
 Significant reduction in tumor burden (15-29%) was observed in 25% (3 patients)
 Durable disease control (≥16 weeks) was observed in 50% (6 patients)
 Five patients are still on-going
o PD was the best response in 25% (3 patients)
 In seven patients in whom FGFR2 fusion was not identified, PD was the best response
 ARQ 087 showed a manageable safety profile with mostly Grade 1-2 adverse events
 Increased FGF19 levels may be a potential surrogate marker for FGFR receptor engagement
 Further development of ARQ 087 as monotherapy or in combination with other anti-cancer agents as second or first line therapy for patients with iCCA with
FGFR2 fusion is deemed feasible considering its favorable safety profile and preliminary evidence of anti-cancer activity5
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METHODS
Study Design and Assessments
Table 1. Patient Characteristics
Table 3. FGFR2 Fusion and the Best Tumor Response
Table 2. Patient Disposition
Study Endpoints
Secondary Endpoints
Primary Endpoints
Evaluation of markers of the FGF signaling pathway
Safety and tolerability in patients with advanced solid
tumors (Part 1) and with FGFR genetic alterations,
including iCCA with FGFR2 fusion (Part 2)
Secondary Endpoints
• Pharmacokinetic profile, incl. food effect (Part 1)
• MTD and/or Recommended Phase 2 Dose (RP2D)
(Part 1)
• Pharmacodynamic activity
• Preliminary evidence of anti-tumor activity and
biomarker evidence of target inhibition
• Target patient-population, e.g., iCCA w/FGFR2 fusion
or other tumors w/FGFR genetic alterations
Exploratory Endpoints
• Association between markers of the FGFR
(specifically FGFR2) signaling pathway, toxicity and
clinical activity
•
Key Eligibility Criteria
• Male/Female ≥ 18 years of age; ECOG PS ≤ 2
• Life expectancy ≥ 12 weeks
• Known (documented) and/or confirmed FGFR genetic alterations, incl.
iCCA with FGFR2 gene fusion
• Availability of archival tissue and/or agreement to undergo paired tumor
biopsy (optional), if feasible
• Evaluable or measurable disease
• Adequate bone marrow, cardiovascular, hepatic and renal function
• Failure to respond to standard therapy or patients for whom standard
therapy does not exist
o ≤ 2 prior systemic regimens with confirmed disease progression
o iCCA treatment-naïve pts w/FGFR2 fusion who may benefit from
treatment with ARQ 087
• No concurrent serious co-morbidities that could limit patients’ full
participation and compliance
• No previous treatment with FGFR inhibitors
• No prior anti-cancer treatment within 4 wks prior to dosing or 5 times
the half-life (which ever is longer)
Parameters iCCAn=21 (%)
Age yrs/median (min, max) 64 (39, 81)
Sex: Male/Female 8 (38%) / 13 (62%)
Race: White/Black 20 (95%) / 1 (5%)
ECOG PS: 0/1 12 (57%) / 9 (43%)
Prior surgery 11 (52%)
Prior radiation therapy 3 (14%)
Prior systemic therapy 19 (90%)
Prior systemic therapy (≥2) 11 (52%)
Number of regimens: 0 2 (10%)
Number of regimens: 1 8 (38%)
Number of regimens: 2 6 (29%)
Number of regimens: 3 3 (14%)
Number of regimens: ≥ 4 2 (10%)
As of 6-June-2016, 21 patients with iCCA were treated with ARQ 087 at 400 or 300 mg qd dose levels. Mutation status by NGS or FISH was reported in 20 patients, including 14 patients with FGFR2 fusion. Radiographic response was assessed in 18 patients
Disposition iCCAn=21 (%)
Time on treatment
Mean (SD) 93.1 (66.9)
Median time on study treatment, days
(Min, Max)
57 (19, 289)
Treatment status
Ongoing 7 (33%)
Reasons for treatmentdiscontinuation
Progressive Disease (PD) 11 (52%)
Physician’s decision
Withdrawal consent
2 (10%)
1 (5%)
No FGFR2 Genetic Aberration Detected
(N=7)
ID # FGFR status Mutational status Best Response
0059 no tissue no tissue SD (17%↑)
0065 not identified BAP1 H169Q PD (62%↑)
0075 not identified ERBB3 amp; PBRM1 PD (13%↑)
0070 not identified IDH1; ARID1A;
PBRM1
n/a (DOD)
0078 not identified BCR-ABL1 fusion;
PTEN FBXW7;
NOTCH2; TP53
PD (69%↑)
0082 not identified IDH2 PD (27%↑)
0083 not identified BRAF; ARIDA1; CHD4 PD( 14%↑)
Table 4. Adverse Events Summary
iCCA
n=21 (%)*
Number of patients with any adverse
event (AE)
21 (100%)
Number of patients with ARQ 087-
related AE
19 (90%)
Number of patients with ARQ 087-
related Severe (≥Grade 3) AE
5 (24%)
Number of patients with treatment
interruption due to ARQ 087-related AE
6 (29%)
• None of the patients were discontinued from the
treatment due to ARQ 087-related AE
• No ARQ 087-related SAE or death were reported as of
data cutoff date
Table 5. Most Common (≥10%) ARQ 087-related Adverse Events
Figure 3. Pharmacodynamic Evaluation3
FGF19 levels were dramatically increased
in the majority of iCCA patients with
FGFR2 fusion.
FGF21 levels were significantly changed
only in one patient with iCCA with FGFR2
fusion.
FGF23 levels were generally lower than
other FGFs monitored; there is no clear
trend in observed changes.
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Figure 1. Best % Change from Baseline in Size of Target
Lesions and Duration of Exposure
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Figure 2. Decreases in Tumor Burden
Baseline Cycle 5 Day 1
Patient 0088 with iCCA
(FGFR2 fusion) whose
disease progressed after one
prior regimen of systemic
therapy had a partial
response: 44% decrease in
tumor burden, completed 4
cycles (ongoing). Cycle 5 Day 1Baseline
Patient 0060 with iCCA
(FGFR2 KIAA1217 fusion)
whose disease
progressed after four
prior regimens of
systemic therapy had a
partial response: 32%
decrease in tumor
burden, completed 10
cycles.
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FGFR2 Genetic Aberration
(N=14)
ID # FGFR status Mutational status Best Response
0060 FGFR2-
KIAA1217
KRAS/LYN/MYC amp
MLL2
PR (32%↓)
0063 FGFR2-BICC1 FBXW7; BAP1 PR (35%↓)
0088 FGFR2 fusion* unknown PR (44%↓) 
0076 FGFR2-CCDC6 IDH2; BAP1 SD (25%↓)
0093 FGFR2 fusion* unknown SD (26%↓) 
0087 FGFR2 fusion* unknown SD (18%↓) 
0089 FGFR2-BFSP2 &
trunc.intron 17
BRCA2 SD (11%↓) 
0092 FGFR2-BICC1 BAP1; AKT3 amp SD (7%↓) 
0091 FGFR2 fusion* unknown SD (5%↑)
0090 FGFR2 fusion* unknown PD (9%↓)**
0074 FGFR2-TACC1 STK11; TSC1; ATM PD (0%)**
0080 FGFR2-BICC1 CDKN2; TP53 EPHA3
amp MUTYHY
PD (16%↑)**
0096 FGFR2 fusion* unknown pending
0097 FGFR2-TACC2 not identified Pending
Preferred Terms All Grades (n=21)(%) Grade ≥3 (n=21)(%)
Dry Mouth 8 (38%) –
Fatigue 8 (38%) 1 (5%)
Nausea 7 (3%) –
Alanine Aminotransferase Increased 5 (24%) 1 (5%)
Dysgeusia 5 (24%) –
Aspartate Aminotransferase Increased 3 (14%) 2 (10%)
Decreased Appetite 3 (14%) –
Vision Blurred 3 (14%) 1 (5%)
Vomiting 3 (14%) 1 (5%)
Diarrhoea 3 (14%) –
Stomatitis 3 (14%) 1 (5%)
Alopecia 2 (10%) –
Anemia 2 (10%) 1 (5%)
Asthenia 2 (10%) –
Dermatitis 2 (10%) –
Dizziness 2 (10%) –
Headache 2 (10%) –
Neuropathy Peripheral 2 (10%) –
Tumor control (complete or partial response or stable disease) was achieved in one of seven iCCA pts
in whom FGFR2 fusions were not identified and in nine of twelve pts with iCCA with FGFR2 fusions.
*FGFR2 status tested by FISH
** new lesion
00XX bold/underline numbers mean the pts are still ongoing
SD - stable disease
PR - partial response
Study Design
This is an open-label multi-center Phase 1/2 dose-escalation (Part 1) and signal-finding (Part 2)
study of ARQ 087. Part 1 results were reported previously2. Part 2 of the study is ongoing
(NCT01752920).
• Dose Escalation/Part 1: December 2012 – November 2015 – completed
• Cohorts 1-4: dose was doubled
• Cohort 5 and in all subsequent cohorts: modified Fibonacci scheme was implemented
• 3+3 patients per cohort (if Dose Limited Toxicity (DLT), standard DLT criteria )
• Maximum Tolerated Dose (MTD) if ≤ 1 DLT out of 6 treated patients
• Expanded cohort/Part 2: December 2015 – ongoing
Assessments
Assessments included response by RECIST v1.1 (investigative sites’ and independent readers) at
baseline and every 8 weeks (wks), safety (physical examination, vital signs, Eastern Cooperative
Oncology Group Performance Status (ECOG PS), laboratory tests), plasma concentrations of
phosphate and FGF19, 21, 23 (potential biomarkers). Treatment-emergent adverse events (TEAE)
were graded according to the National Cancer Institute Common Terminology Criteria for Adverse
Events (NCI CTCAE version 4.03).
